Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Phase II study of biweekly versus fractionated triweekly Taxotere + cisplatin + fluorouracil in advanced gastric and gastro-esophageal junction cancer
2008-000551-10Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Mar 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel, cisplatin and fluorouracil in gastric adenocarcinoma, gastroesophageal adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Institut Jules Bordet. Primary endpoint: Toxicity comparison between regimens. Started Mar 2008; status: completed.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2008-000551-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000551-10.